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Abstract 
Knockout of genes encoding metabotropic glutamate receptor 5 (mGluR5) or its endogenous regulators, 
such as Norbin, induce a schizophrenia-like phenotype in rodents, suggesting dysregulation of mGluR5 in 
schizophrenia. Human genetic and pharmacological animal studies support this hypothesis, but no 
studies have explored mGluR5 dysfunction at the molecular level in the postmortem schizophrenia brain. 
We assessed mGluR5 mRNA and protein levels in the dorsolateral prefrontal cortex (DLPFC) using a large 
cohort of schizophrenia and control subjects (n = 37/group), and additionally measured protein levels of 
recently discovered mGluR5 endogenous regulators, Norbin (neurochondrin), Tamalin (GRASP-1), and 
Preso1 (FRMPD4), which regulate mGluR5 localization, internalization and signaling. While mGluR5 mRNA 
expression was unchanged, mGluR5 protein levels were significantly higher in schizophrenia subjects 
compared to controls (total: +22 %; dimer: +54 %; p < 0.001). Conversely, mGluR5 regulatory proteins were 
expressed at lower levels in schizophrenia subjects compared to controls (Norbin −37 %, p < 0.001; 
Tamalin −30 %, p = 0.084; Preso1 −29 %, p = 0.001). mGluR5 protein was significantly associated with 
mGluR5 mRNA and mGluR5 endogenous regulators in control subjects, but these associations were lost 
in schizophrenia subjects. Lastly, there were no associations between protein measures and lifetime 
antipsychotic history in schizophrenia subjects. To confirm no antipsychotic influence, all proteins were 
measured in the prefrontal cortex of rats exposed to haloperidol or olanzapine; there were no effects of 
antipsychotic drug treatment on mGluR5, Norbin, Tamalin or Preso1. The results from our study provide 
compelling evidence that mGluR5 regulation is altered in schizophrenia, likely contributing to the altered 
glutamatergic signaling that is associated with the disorder. 
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Knockout of genes encoding metabotropic glutamate receptor 5 (mGluR5) or its endogenous 
regulators, such as Norbin, induce a schizophrenia-like phenotype in rodents, suggesting 
dysregulation of mGluR5 in schizophrenia. Human genetic and pharmacological animal studies 
support this hypothesis, but no studies have explored mGluR5 dysfunction at the molecular level in 
the postmortem schizophrenia brain. We assessed mGluR5 mRNA and protein levels in the 
dorsolateral prefrontal cortex (DLPFC) using a large cohort of schizophrenia and control subjects 
(n=37/group), and additionally measured protein levels of recently discovered mGluR5 endogenous 
regulators, Norbin (neurochondrin), Tamalin (GRASP-1), and Preso1 (FRMPD4), which regulate 
mGluR5 localization, internalization and signaling. Whilst mGluR5 mRNA expression was 
unchanged, mGluR5 protein levels were significantly higher in schizophrenia subjects compared to 
controls (total: +22%; dimer: +54%; p<0.001). Conversely, mGluR5 regulatory proteins were 
expressed at lower levels in schizophrenia subjects compared to controls (Norbin -37%, p<0.001; 
Tamalin -30%, p=0.084; Preso1 -29%, p=0.001). mGluR5 protein was significantly associated with 
mGluR5 mRNA and mGluR5 endogenous regulators in control subjects, but these associations were 
lost in schizophrenia subjects. Lastly, there were no associations between protein measures and 
lifetime antipsychotic history in schizophrenia subjects. To confirm no antipsychotic influence, all 
proteins were measured in the prefrontal cortex of rats exposed to haloperidol or olanzapine; there 
were no effects of antipsychotic drug treatment on mGluR5, Norbin, Tamalin or Preso1. The results 
from our study provide compelling evidence that mGluR5 regulation is altered in schizophrenia, 
likely contributing to the altered glutamatergic signaling that is associated with the disorder. 
 
 










Deficits in executive function, reasoning abilities and working memory seen in patients with 
schizophrenia are largely attributable to altered glutamate signaling in cortical regions [13]. These 
neurocognitive deficits are arguably the most debilitating aspects of the disorder, and the most 
difficult to treat [33]. While we and others have found changes in the main cortical ionotropic 
glutamate receptor, the N-methyl-D-aspartate receptor (NMDAR) in schizophrenia [1, 39], other 
glutamate receptors are likely to be involved. Accumulating evidence strongly suggests the 
involvement of metabotropic glutamate receptor subtype 5 (mGluR5) in the emergence of glutamate 
deficits in schizophrenia. Firstly, mGluR5 antagonism in rodents produces a range of schizophrenia-
related behaviors, such as deficits in social interaction, working and spatial memory, instrumental 
learning, and amplification of deficits induced by NMDAR antagonists. Secondly, mGluR5 knockout 
mice display schizophrenia-like behaviors, including reduced sensorimotor gating, impaired spatial 
memory, and sensitivity to deficits induced by NMDAR antagonists or amphetamine. Finally, 
mGluR5 positive allosteric modulators (PAMs) have therapeutic potential in the treatment of 
schizophrenia-like behaviors, particularly the cognitive-like symptoms which are induced in both 
glutamatergic (NMDAR antagonists) and dopaminergic (amphetamine) animal models [see 18]. 
 
Based on these studies, a role of mGluR5 in schizophrenia pathophysiology has been hypothesized. 
Ohnuma and colleagues first reported that mGluR5 mRNA expression was increased in pyramidal 
cell layers of the superior frontal cortex (Brodmann Area 9; BA9) of schizophrenia subjects [25], 
although more recently, no change was reported in a larger cohort examining the same region [8]. 
Conversely, mGluR5 monomer protein levels were reported to be significantly reduced in the same 
region [8]. However, other postmortem studies in cortical regions of patients with schizophrenia have 
reported that mGluR5 mRNA, protein and binding levels are unaltered [see 18, 23]. These 
inconsistent results might be due to region-specific differences, small sample sizes and/or other 
methodological differences in protein detection, such as the examination of monomer versus dimer 
protein expression [23]. A potential explanation for pathological disturbances in mGluR5 is abnormal 
regulation, caused by alterations to key proteins that regulate mGluR5 signaling, localization and 
trafficking as previously suggested by us [23] and others [4]. These type of disturbances have been 
previously reported for other aspects of the glutamatergic system [19]. In support of this hypothesis, 
proteins that regulate glutamatergic receptors (e.g. NMDAR, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor and mGluRs), including Homer1, are reportedly altered in some 
schizophrenia studies [see 35]. However, additional proteins that critically modulate mGluR5 activity 
have also been identified [12, 14, 37], but have not yet been directly examined in the brains of people 
with schizophrenia. 
 
Of the known mGluR5 endogenous regulators, Norbin, Tamalin and Preso1 have particularly 
distinctive roles in mGluR5 modulation. The cytoplasmic protein Norbin (neurochondrin) is reported 
to increase mGluR5 cell surface localization and positively regulate mGluR5 signaling in in vitro 
systems [38]. Norbin is also critically involved in neurite outgrowth, and thus neuronal plasticity and 
cognitive functioning [22, 30]. Cortical Norbin knock-out mice have reduced mGluR5 cell surface 
expression and function, and display strong schizophrenia-like behaviors [38]. Tamalin (also named 
GRP1-associated scaffold protein 1 or GRASP-1), is a 95 kDa postsynaptic density protein (PSD-
95)/discs-large/ ZO-1 or PDZ) domain-containing scaffold, which plays a fundamental role in the 
localization of mGluR5 from the soma to the neuritic processes in cultured hippocampal neurons [14]. 
In accordance, disruption of Tamalin/mGluR5 couplings causes reduced mGluR5 cell surface 
expression and increased agonist-induced internalization of mGluR5 in cellular assays [34]. 
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Furthermore, the scaffold protein Preso1 (FRMPD4) was also reported to be essential to mGluR5 
signaling, with Preso1-dependent phosphorylation of mGluR5 serving to down-regulate mGluR5 
signaling under control conditions in cellular assays, whilst Preso1−/− mice exhibit characteristics 
reminiscent of enhanced mGluR5 signaling [12]. Preso1 additionally modulates mGluR5 coupling to 
the scaffold protein Homer [12], which has been previously associated with schizophrenia [6, 31]. 
However, the role of Preso1 in schizophrenia-relevant paradigms has not been assessed. Together, 
Norbin, Tamalin and Preso1 have been shown to critically modulate mGluR5 localization, trafficking 
and signaling, and may thus serve as markers of these functions in postmortem studies where 
manipulation of the signaling system is not possible. Furthermore, considering that mGluR5 activity 
could be impaired should these endogenous regulators be altered, it is crucial that they are considered 
in the context of schizophrenia. 
 
We therefore explored in the present study whether patients with schizophrenia express altered 
mRNA and protein levels of mGluR5 compared to controls, in a well-powered postmortem cohort. 
We specifically examined the dorsolateral prefrontal cortex (DLPFC; BA46) as this region is highly 
implicated in schizophrenia pathology due to its role in the development of cognitive deficits [2, 39]. 
For the first time, we also assessed the protein levels of novel mGluR5 endogenous regulators, Norbin, 
Tamalin and Preso1, as markers of mGluR5 localization, trafficking and signaling. Based on the 
extensive evidence that reduction of mGluR5 activity causes behavioral phenotypes associated with 
schizophrenia [see 18], our hypotheses were that levels of mGluR5 and endogenous modulators 
would be decreased in the DLPFC of people with schizophrenia. Considering that premortem 
medication history is a confounding factor in human postmortem studies, we also investigated 
whether the influences of commonly used antipsychotic drug treatments extend to the mGluR5 system. 
We therefore conducted the same protein analyses in a pharmacological animal model exposed to 
typical (haloperidol) or atypical (olanzapine) antipsychotic medication. 
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Materials and Methods 
 
Human postmortem brain samples 
Human DLPFC tissues were obtained from the New South Wales Brain Bank Network (Sydney, 
Australia). The complete cohort consisted of 37 schizophrenia (including 7 schizoaffective) 
postmortem brain samples and 37 controls (with no history of psychiatric diagnosis), which were 
matched according to tissue pH, age at death, postmortem interval and RNA integrity number (RIN) 
(Table 1). Schizophrenia subjects were diagnosed according to the Diagnostic and Statistical Manual 
of Mental Disorders IV. Antipsychotic drug treatment premortem was standardized to lifetime 
chlorpromazine equivalent for each patient. Antidepressant drug treatment history was also specified 
on a qualitative scale (i.e. yes/no). Further details regarding clinical, demographic and tissue 
characterization of the cohort has been described previously [40]. This study was approved by the 
Human Research Ethics Committees at the University of Wollongong (HE99/222) and the University 
of New South Wales (HREC07261). 
 
Human brain tissue preparation 
Anatomical identification and preparation of the tissue has been previously described in detail [40]. 
Briefly, samples corresponding to BA46 were dissected from coronal blocks from the middle frontal 
gyrus, anterior to the genu of the corpus callosum. For gene expression analyses, 300mg of frozen 
tissue was pulverized on dry ice. Trizol was used to extract total RNA, and the quality was analyzed 
using the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, USA). For immunoblot studies, 
40mg of frozen tissue was homogenized in 400µL of homogenizing buffer, containing 50mM Tris pH 
7.5, 50% glycerol and 1:20 (by volume) protease inhibitor cocktail (Sigma, Sydney, Australia). 
Homogenates were diluted to a total protein concentration of 2µg/µl, and concentration was verified 
by Bradford and bicinchoninic acid assays. 
 
Animal housing and treatment 
This study was designed to assess whether commonly used antipsychotic medications affect the 
protein expression of mGluR5 and mGluR5 endogenous regulators. Adult male Sprague-Dawley rats 
at 10-weeks of age were purchased from the Animal Resource Centre (Perth, Australia) and single 
housed under standard conditions with food and water available ad libitum. It should be noted that 
although animals were singly housed to ensure accurate dosage of APDs, measures were taken to 
ensure animals were not socially isolated: wire cages were stored in an adjoining manner to allow for 
social interaction between cages, and animals were given pipes for hiding and wooden toys to chew, 
to reduce any stress caused by separation.  
 
After one week of acclimatization, rats were distributed into 9 treatment groups (3 treatments x 3 
treatment-durations; n=6/group), as described previously [17]. Animals were fed prepared food pellets 
3 times/day at 8 hour intervals, containing either:  (1) typical antipsychotic, haloperidol (0.1mg/kg 
body weight; daily total 0.3mg/kg), (2) atypical antipsychotic, olanzapine (1mg/kg body weight; daily 
total 3mg/kg), (3) vehicle control (empty food pellets), for short term (8 days), medium term (15 
days) and long term (35 days) durations. Consumption of food pellets was visually validated. 
Antipsychotic doses and treatment durations were chosen to model a clinical setting [11, 41]. All 
animal experiments in this study were approved by the University of Wollongong Animal Ethics 
Committee (AE10/18) and complied with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes. 
 
Animal brain tissue preparation 
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Rats were euthanized 48 hours following the final treatment using carbon dioxide asphyxiation. 
Brains were rapidly removed, and the prefrontal cortex (PFC; prelimbic area, Bregma 3.7-2.7) was 
dissected on ice and snap frozen in liquid nitrogen, and stored at -80C. Identification of rat brain 
regions for quantification was based on a standard rat brain atlas [26]. Tissue was homogenized in 
NP-40 lysis buffer (Invitrogen), containing beta-glycerophosphate and pheylmethanesulfonylfluoride 
protease cocktail inhibitor cocktail (Sigma). Protein concentration was determined by detergent-
compatible colorimetric assay (BioRad, Gladesville, Australia), according to the manufacturer’s 
instructions. 
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis  
Transcript levels of mGluR5 mRNA were measured by qRT-PCR as previously described [40]. 
Briefly, total RNA was extracted using Trizol as per the manufacturer’s protocol (Invitrogen) and 
RNA quality was determined using Agilent Bioanalyzer. Complementary DNA synthesis was 
performed using Superscript III (Invitrogen), in triplicate and using 3µg total RNA per sample 
(pooled). qRT-PCR for mGluR5 mRNA was subsequently performed using TaqMan Gene Expression 
Assays (Applied Biosystems, Hs00168275_m1) and the ABI Prism 7900HT system. Quantity mean 
for expression was normalized to four housekeeping genes - ubiquitin C (Hs00824723-m1), ß-actin 
(Hs99999903-m1), glyceraldehyde-3-phosphate dehydrogenase (Hs99999905-m1), and TATA box 
binding protein (Hs00427620- m1) - that have been reported not to differ between the diagnostic 
groups in the same brain region, same cohort and same cDNA synthesis [40]. 
 
Immunoblot 
Relative protein densities were determined by immunoblot. The following polyclonal antibodies were 
used: mGluR5 (ABCAM ab27190 [17]), Tamalin (ABCAM ab30576 [32]), Preso1 (Santa Cruz sc-
242862 [16, 27]) and Norbin (ABCAM ab130507). Immunoblotting was performed as described 
previously [17], with minor modifications optimized for the measurement of each protein of interest 
(Table 1). Samples were loaded at 5µg and 10µg for all proteins assessed in human and rat brain 
samples respectively. Samples were visualized using an enhanced chemiluminescent detection kit 
(BioRad). Band density was detected by the Gel Doc 2200 Pro (Carestream Molecular Imaging, USA) 
and quantified with Carestream MI software (v 5.0.4.44, Carestream Molecular Imaging). All bands 
were within the linear range of detection. Protein measures were subsequently normalized to the 
respective ß-actin density (i.e. [band intensity of protein] ÷ [band intensity of respective ß-actin]), 
which was unaltered in the present study and has also been reported as a reliable standard in this 
postmortem cohort [40]. Actin-normalised values were then renormalised to a pooled sample, which 
was run on each gel to control for any gel-to-gel variability. Each sample was run in duplicate and the 
average value of both samples was then used in the statistical analyses. Experiments and 
quantification were performed blind to diagnosis (human) or treatment group (rat).  
 
Statistical Analysis of Human Data 
Statistical analyses were performed with SPSS version 19. Significance was set to p<0.05 and data are 
presented as mean ± standard error of the mean. mGluR5 mRNA expression was normally distributed. 
As distributions for all protein measures were skewed to the right (Kolmogorov-Smirnov: d=0.161-
0.224, p<0.001), normalized distribution for these proteins was achieved by transforming to the 
natural logarithm of the relative protein values. Outliers were screened as mean ± 2 standard 
deviations and were removed. No subjects were removed from the mRNA analysis, although 2 
subjects were removed on average from each protein analysis. 
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Analyses of variance (ANOVA) were used to detect differences in protein expression between 
diagnostic groups (schizophrenia/control) as well as gender (male/female), hemisphere (left/right) and 
antidepressant history (yes/no). Spearman’s correlations were used to determine whether sample 
characteristics (age at death, pH, postmortem interval, RIN, brain weight and freezer storage time) 
were associated with protein measures. Analyses of covariance (ANCOVA) for diagnostic effects on 
protein expression were subsequently performed, accounting for factors that were associated with 
protein measures, as determined by the Spearman’s correlations. Additional measures of disease 
characteristics were correlated specifically with the schizophrenia group (lifetime antipsychotic drug 
history, age of disease onset and duration of illness). 
 
Statistical Analysis of Animal Data 
For analysis of animal data, statistics were performed with SPSS, significance was set to p<0.05 and 
data presented as the mean ± standard error of the mean. Differences between treatment 
(haloperidol/olanzapine/vehicle) x duration (short term/medium term/long term) were analyzed by 









Detection of mRNA and proteins 
For qRT-PCR of mGluR5 mRNA, control samples (no template and no reverse transcriptase enzyme) 
did not produce a signal during measurement of mGluR5 mRNA expression, where we obtained 
robust signal from all samples and a reliable standard curve (slope=-3.42, y=31.27). For protein 
measurements, mGluR5 monomer was detected as a single band at 135kDa whilst the mGluR5 dimer 
was detected at 270kDa. As mGluR5 was detected at two molecular weights, mGluR5 dimer and total 
(sum of monomer and dimer) levels are reported. We have previously reported only mGluR5 
monomer levels [17]; total and dimer measures in this study were analyzed from the same 
experimental run. Norbin (79kDa) and Tamalin (96kDa) proteins were identified as single bands at 
the expected molecular weights in the human DLPFC (Fig. 1a, Fig. S1) as well as in the rat PFC. 
Preso1 probing resulted in several bands; a single specific band was verified and quantified at 144kDa 
by peptide pre-absorption/neutralization, and all other non-specific bands thus were excluded (Fig. 
S1; see Supplementary Methods). ß-Actin was reliably detected at 45kDa (Fig. 1a). 
 
mGluR5 mRNA is unaltered and mGluR5 protein is increased in the DLPFC in schizophrenia 
mGluR5 mRNA expression was not altered in DLPFC of schizophrenia subjects compared to controls 
after co-varying for brain pH, age at death, RIN and brain weight (F1,68=0.009, p=0.924; Fig. 1b), 
which were variables that correlated with mRNA expression (Table S2). There was no effect of 
gender or hemisphere on mGluR5 mRNA expression. We have previously reported no change in 
mGluR5 monomer levels in this cohort in DLPFC [17]. However, mGluR5 dimer expression was 
53.5% higher in schizophrenia subjects compared to controls (F1,70=8.688, p<0.001; co-varying for 
freezer storage time, which correlated with dimer levels [Table S2]: F1,69=44.808,  p<0.001). Total 
(monomer and dimer) mGluR5 protein was significantly increased by 21.9% in schizophrenia 
subjects compared to controls (F1,68=19.090, p<0.001; Fig. 1b). Significance was maintained after co-
varying for freezer storage time (F1,67=17.45, p<0.001 [correlation values in Table S2]). There were 
no effects of gender and hemisphere on mGluR5. 
 
Norbin, Tamalin and Preso1 proteins are reduced in the DLPFC in schizophrenia 
Protein levels of all three mGluR5 endogenous regulators examined were significantly decreased in 
schizophrenia subjects (Fig. 1c). Specifically, Norbin was decreased by 37.4% (F1,70=34.497, 
p<0.001), Tamalin by 30.4% (F1,70=4.428, p=0.039), and Preso1 by 21.5% (F1,70=5.607, p=0.021). 
Significance was maintained for Norbin and Preso1 after co-varying for freezer storage time, which 
was significantly correlated with these protein levels (Table S2); however Tamalin was not 
significantly different after co-varying for freezer storage time and age at death (F1,69=3.075, 
p=0.084), due to a strong effect of freezer storage time (r=-4.75, p<0.001) and age at death in control 
subjects (r=0.353, p=0.032; correlation values in Table S2). There were no effects of gender or 
hemisphere on Norbin, Tamalin or Preso1 protein levels (p>0.050). 
 
Correlations with demographic measures, disease characteristics and medication estimates 
Spearman’s correlations were performed to assess any relationships between mGluR5 mRNA 
expression and protein measures of mGluR5, Norbin, Tamalin and Preso1 with age at death, RIN, 
freezer storage time, brain pH, postmortem interval and brain weight (Table S2). 
 
mGluR5 mRNA expression was significantly associated with brain pH, age at death, RIN and brain 
weight overall in all subjects. Specifically in control subjects, mGluR5 mRNA was negatively 
correlated with age at death and positively correlated with brain weight. In schizophrenia subjects, 
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mGluR5 mRNA expression was weakly associated with pH, RIN, and brain weight. There were no 
effects of illness duration, age of disease onset or lifetime antipsychotic drug history on mGluR5 
mRNA in schizophrenia subjects, nor were there any effects of antidepressant medication (yes/no: t-
35=0.299, p=0.588). 
 
There was a significant interaction between mGluR5 total protein with freezer storage time in both 
control and schizophrenia subjects when analyzed separately, but not overall. mGluR5 dimer was also 
significantly correlated with freezer storage time an RIN in schizophrenia subjects. An effect of 
freezer storage time was seen on Norbin, Tamalin and Preso1. There were no other significant 
correlations with protein measures of mGluR5 endogenous modulators in all subjects. Specifically in 
control subjects, Tamalin, but not Norbin or Preso1, was negatively associated with age at death, 
while all proteins were associated with freezer storage time. In the schizophrenia group, there was a 
negative association of age of disease onset with measures of Norbin and Preso1 only, and an effect of 
freezer storage time on Norbin. There was no effect of illness duration or lifetime antipsychotic drug 
history on mGluR5 (total or dimer), Norbin, Tamalin or Preso1. 
 
Relationships of mGluR5 protein with mGluR5 mRNA, Norbin, Tamalin and Preso1 proteins in 
the DLPFC 
A distinct relationship was seen between mGluR5 total protein and mGluR5 mRNA expression, as 
well as protein measures of mGluR5 with Norbin, Tamalin and Preso1 (Fig. 2). While mGluR5 total 
protein was positively associated with mGluR5 mRNA expression in control subjects (r=0.361, 
p=0.030), this correlation was lost in schizophrenia subjects. Similarly, mGluR5 protein was strongly 
and negatively associated with all endogenous regulators in the control group (Norbin: r=-0.657, 
p<0.001; Tamalin: r=-0.560, p<0.001; Preso1: r=-0.428, p=0.009), but this association was not 
present in the schizophrenia group (Norbin: r=0.096, p=0.578; Tamalin: r=0.202, p=0.238; Preso1 
r=0.080, p=0.644). An extensive list of correlation values is included in Table S3. 
 
Effects of antipsychotic drug treatment on mGluR5 and its endogenous regulators in the 
prefrontal cortex  
To assess the effects of antipsychotic medications on the mGluR5 system, two-way ANOVA was 
used to compare the effects of haloperidol, olanzapine and vehicle/control treatment (8, 16 or 36 days) 
on protein levels of mGluR5 (total, monomer, dimer), Norbin, Tamalin and Preso1 in the PFC of rats. 
There were no significant main effects of treatment or duration on protein expression, nor were there 
any interactions between treatment and duration on protein expression (F>0.050, p>0.961; Fig. 3). 
This is in line with the aforementioned human studies, in which there were no effects of lifetime 
antipsychotic drug medication or antidepressant history on protein measures. 
  





Here, we provide compelling evidence that mGluR5 is dysregulated in the DLPFC (BA46) of patients 
with schizophrenia. We found that whilst mGluR5 mRNA expression levels were not different, 
mGluR5 protein levels were significantly higher in schizophrenia subjects compared to controls (total: 
+22%; dimer: +54%). Conversely, in the same samples, mGluR5 endogenous regulators Norbin (-
37%), Tamalin (-30%; p=0.084 after co-varying for confounding factors) and Preso1 (-29%) were 
expressed at substantially lower levels in the DLPFC of schizophrenia subjects compared to control 
subjects. mGluR5 mRNA, Norbin, Tamalin and Preso1 proteins were significantly associated with 
mGluR5 protein levels in control subjects, but these associations were lost in schizophrenia subjects. 
Lastly, there was no effect of current antipsychotic drug treatment on mGluR5 or mGluR5 
endogenous regulators in either human or animal studies. Thus, the present findings suggest that 
mGluR5 regulation is altered in the DLPFC in schizophrenia, but not influenced by current 
therapeutics. 
 
In this study, higher mGluR5 protein expression was detected in schizophrenia subjects compared to 
controls, but there was no difference in mGluR5 mRNA expression in these same cases. Previous 
studies have similarly reported no change in mGluR5 mRNA expression in the adjacent BA9 region 
of schizophrenia subjects [8, 36] accompanied by altered mGluR5 protein levels [8]. These findings 
support the existence of dissociation between mGluR5 mRNA and protein levels in schizophrenia 
subjects. Our results also revealed that mGluR5 mRNA expression was significantly and positively 
associated with mGluR5 protein in control subjects, but not schizophrenia subjects. mRNA and 
protein have differing half-lives due to variations in protein synthesis and degradation, so that the 
change in protein concentration is equal to the “rate of translation” minus the “rate of degradation” 
[10]. As we report no change in the rate of translation (as measured by mGluR5 mRNA expression), 
the loss of association between mGluR5 mRNA and protein in schizophrenia is likely indicative of 
reduced receptor degradation and a prolonged lifespan of mGluR5 proteins. This may be owing to 
slowed mGluR5 trafficking, as we further report reduced levels of the mGluR5 trafficking proteins 
Norbin and Tamalin in this study; we however caution that Tamalin did not reach significance after 
covarying for confounding factors (p=0.084), but due to the large magnitude of change (30%) and 
significant correlations of Tamalin with the other measures (Fig 4c, Table S3, and discussed below), 
we will further discuss this finding. 
 
Norbin and Tamalin bind to amino acid residues on the intracellular terminus of mGluR5, and 
critically regulate mGluR5 cell surface localization and intracellular trafficking [14, 15, 34, 38]. 
Accordingly, in cultures derived from cortical Norbin knockout mice, mGluR5 cell surface 
localization was reduced [38]. Kitano and colleagues also determined that Tamalin was required for 
transport of mGluR5 from the soma to neuritic processes [14], whilst Timms et al. demonstrated that 
deletion of the Tamalin binding site on mGluR5 resulted in increased agonist-dependent 
internalization of mGluR5 [34]. This evidence suggests reductions in Norbin and Tamalin 
simultaneously cause reduced trafficking of mGluR5 protein, decreased cell surface expression, and 
intracellular retention of mGluR5 (Fig. 4a-b). In view of the fact that G-protein coupled receptor 
dimerization occurs soon after biosynthesis [20], it is also likely that these captive mGluR5 are in the 
dimer form. A growing body of evidence suggests that mGluR5 proteins are only functional in the 
form of disulfide-linked dimers [5, 29], suggesting an increase in mGluR5 dimers represents an 
increase in functional mGluR5 units in the present study. However, considering reduced mGluR5 
signaling (by mGluR5 knockout or pharmacological antagonism) produces schizophrenia-like 
behaviors, and mGluR5 PAMs have therapeutic efficacy in preclinical rodent models [see 18], we 
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hypothesize a model of mGluR5 dysregulation in which higher protein expression and dimer units 
does not represent increased activity and/or function in the schizophrenia brain, but rather, alterations 
to mGluR5 localization (Fig 4a and b) and also signaling (Fig. 4a and c).  
 
In addition to a trafficking deficit, our results further indicate altered mGluR5 signaling as substantial 
reductions were observed in Norbin and Preso1 proteins, which are critical regulators of mGluR5 
signaling [12, 38]. Firstly, Norbin was demonstrated to enhance mGluR5 signaling in cell-based 
assays, by increasing inositol phosphates, intracellular calcium release, and ERK1/2 phosphorylation 
compared to mGluR5 expression alone [38], indicating decreased mGluR5 signaling due to reduced 
Norbin expression in the present study (Fig. 4a). In contrast, Preso1 reportedly inhibits mGluR5-
dependent intracellular release and ERK1/2 phosphorylation, via Homer1/2/3 under control 
conditions [12], indicating disinhibition of mGluR5 signaling due to reduced Preso1 in the present 
study (Fig. 4c). Notably, Preso1 and Norbin levels are positively correlated in control subjects 
(r=0.559, p=0.003) but not schizophrenia subjects (r=0.152, p=0.368), supporting the notion of 
opposing functions and thus a balance of Norbin:Preso1 under control conditions. Although further 
studies will be required to determine whether reductions in Norbin and Preso1 are causal or 
compensatory to mGluR5 dysregulation, this finding suggests that the ratio of Norbin:Preso1 and thus 
positive and negative modulation of mGluR5 is altered in schizophrenia, strongly supporting the 
hypothesis that mGluR5 signaling is affected in the DLPFC in the schizophrenia brain. 
 
It should be noted that the increase in mGluR5 protein levels in the present study was specific to 
mGluR5 dimers, as we previously reported no change in mGluR5 monomers in the same samples in 
the same experimental run [17]. As discussed previously by Corti et al. [3], who similarly reported 
altered dimerization of mGluR3 in the DLPFC in schizophrenia and hypothesized the same of 
mGluR5 [4], there are several possible interpretations of altered monomer and dimer densities. Firstly, 
the composition of heterodimeric complexes involving mGluR5 with structurally similar G-protein 
coupled receptors (such as mGluR1a, adenosine or gamma-aminobutyric acid (GABA)-B receptors) 
has been proposed [9, 29], presenting the possibility of alterations to the ratio of 
heterodimers:homodimers, and thus mGluR5 function and activity in schizophrenia. Furthermore, as 
hypothesized for mGluR3, the presence of mutations within mGluR5 and/or altered splicing of 
mGluR5 might affect the formation, affinity and activity of mGluR5 dimers [3, 34]. Lastly, it remains 
unclear whether dimerization might be affected during the perimortem period, or whether dimers 
measured under reducing immunoblot conditions is reflective of physiological levels [7, 23]. Even so, 
considering we found an increase rather than a decrease in mGluR5 dimer levels, it is unlikely that 
these factors impact on the overall results of this study. Further, the mechanisms or molecules 
responsible for regulating mGluR5 dimerization are not known but would be useful for interpreting 
these findings. It is additionally interesting that in the present study, the levels of all measured 
mGluR5 endogenous regulators were negatively correlated with protein levels of mGluR5 in control 
patients, and this association was lost in patients with schizophrenia (Supplementary Table 3). 
Although this finding supports the dissociation of mGluR5 with endogenous regulatory processes in 
the schizophrenia brain, the relationship between mGluR5 and its endogenous regulators under 
control conditions is counter-intuitive and requires further investigation. 
 
We found no associations between mGluR5 and its endogenous regulators with lifetime antipsychotic 
drug treatment in our postmortem human study, and no effects of haloperidol or olanzapine treatment 
on the expression of the mGluR5 system proteins in our animal study. Our results thus strongly 
suggest that the aspects of the mGluR5 system measured in this report are unaffected by commonly 
used antipsychotic drugs. This is in line with our previous work, in which we found that mGluR5 
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binding in the PFC was also unaffected in the same animal model and treatment regime [17]. It is 
notable, however, that these results are reflective of “control” conditions, which would be enhanced 
by follow-up studies of antipsychotic drug treatment in an animal model of schizophrenia. Drugs 
targeting mGluR5 have therapeutic efficacy against cognitive and negative schizophrenia-like deficits 
in animal models [24], while current therapeutics have little efficacy for these symptoms [21]. 
mGluR5-targeting drugs therefore present a compelling adjunct treatment strategy for schizophrenia, 
specifically in relation to cognitive deficits associated with glutamatergic dysfunction. However, it 
should be specifically determined whether mGluR5 target availability is altered in people with 
schizophrenia due to intracellular retention, and whether this will impair the efficacy of novel 
therapeutics aimed at mGluR5. 
 
Using one of the largest postmortem cohorts to date to study mGluR5 and its endogenous regulators, 
we have for the first time established that mGluR5 is dysregulated in schizophrenia. Due to the 
prominent role of cortical glutamate function in the emergence of emotional and cognitive deficits 
associated with schizophrenia, we further suggest that dysregulation of mGluR5 might contribute to 
the cognitive dysfunctions that are observed in these patients. Whilst this study supports the presence 
of mGluR5 dysregulation and/or signaling deficits in schizophrenia, it is important to determine 
whether mGluR5 target availability is altered, and whether this will impair the efficacy of novel 
therapeutics aimed directly at mGluR5. Future postmortem studies focusing on functional assays and 
analyses of protein-protein interactions in specific neuronal populations and/or subcellular 
compartments are thus required to examine the nature of functional alterations to mGluR5 (for 
example, altered phosphorylation, protein misfolding, reduced protein interactions, and/or sequence 
mutations). Further studies investigating the basic processes involved in mGluR5 translation, 
dimerization and regulation (under control conditions) will also be helpful in determining the exact 
processes underlying mGluR5 regulation, the role of mGluR5 in schizophrenia pathology, and how 
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Table 1 Summary of postmortem subject demography for control and schizophrenia groups. 
 
  Control Schizophrenia 
Brain pH 6.66 ± 0.29 6.61 ± 0.30 
Postmortem interval (hours) 24.8 ±10.97 28.8 ± 14.07 
RNA integrity number 7.3 ± 0.57 7.3 ± 0.58 
Age at Death (years) 51.1 ± 2.40 (range: 18–78) 51.3 ± 2.32 (range: 27-75) 
Gender 7 F, 30 M 13 F, 24 M 
Hemisphere 23 L, 14 R 17 L, 20 R 
Freezer Storage Time (months) 81.6 ± 42.7 91.9 ± 37.2 
Age of disease onset (years) - 23.7 ± 6.1 
Duration of illness (years) - 27.62 ± 13.81 
Number patients with antidepressant 
medication history 
- 19 
Lifetime antipsychotic drug medication 
(standardized to chlorpromazine equivalent: 
mg) 
- 702 ± 90 
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Supplementary Fig. 1 Full-length immunoblots for (a) mGluR5, (b) Norbin, (c) Tamalin, and (d) Preso1 (A. with no 
peptide, B. with blocking peptide). mGluR5 (a) appeared as 2 distinct bands at 135kDa (monomer) and 270kDa (dimer) and 
these bands have previously been shown to be specific for mGluR5 in HEK cells transfected with mGluR5 
(www.abcam.com/Metabtropic-Glutamate-Receptor-5-antibody-ab27190). Norbin (b) and Tamalin (c) were reliably 
detected as single bands at the expected molecular weights (79kDa and 96kDa respectively) with no non-specific binding. 
The Preso1 antibody (Santa Cruz sc-242862) produced several bands at various molecular weights (d); A single specific 
band was verified at 144kDa by peptide pre-absorption/neutralization, and this band was quantified. The representation of ß-
actin (e); is taken from the mGluR5 immunoblot which was reprobed with ß-actin as a loading control. ß-actin was measured 





Determination of Preso1 specificity by peptide pre-absorption (FRMPD4 Antibody, Santa Cruz: 
sc-242862 and sc-242862 P) 
Peptide pre-absorption/neutralization was performed according to the protocol described by Santa 
Cruz (http://www.scbt.com/protocols.html?protocol=peptide_neutralization). The highest 
concentration of antibody dilution for which a consistently positive result was achieved, was 
determined to be 1:1000. For blocking/competition, 10µL of antibody, 50µL of peptide and 500µL of 
PBS, was combined and incubated for 2 hours at room temperature. The antibody/peptide solution 
was subsequently diluted up to 10mL with 0.5% skim milk in PBST, and applied to membranes 
containing 15µg of electrophoresed protein from the rat prefrontal cortex. These immunoblots were 





Supplementary Table 1 Immunoblot conditions: all immunoblots were run on bis-tris 
polyacrymalide gels (4-12% Bis-Tris, BioRad), at a loading concentration of 5μg (human) or 10µg 
(rat) of total protein per lane. Samples were reduced with laemmli buffer containing ß-
mercaptoethanol. 





 1o antibody 2o antibody 
Buffer Block Denaturing Dilution 
(human, rat) 
Temp. Time Type Dilution Temp Time 
mGluR5 PBST Skim milk 95˚C for 5min 1:250,  
1:500 
4oC 16 hr Rabbit 1:3000 RT 1 hr 
Tamalin PBST BSA 95˚C for 5min 1:100,  
1:1000 
4oC 16 hr Rabbit 1:3000 RT 1 hr 
Norbin PBST BSA 95˚C for 5min 1:500,  
1:500 
4oC 16 hr Rabbit 1:3000 RT 1 hr 
Preso1 PBST BSA 95˚C for 5min 1:100,  
1:1000 
4oC 16 hr Goat 1:3000 RT 1 hr 
ß-actin As for primary antibody 1:5000,  
1:5000 
RT 1 hr Mouse 1:3000 RT 1 hr 
Abbreviations:  BSA: Bovine serum albumin; mGluR5: metabotropic glutamate receptor 5; PBST: 
phosphate-buffered saline containing Tween-20; RT: room temperature.	  
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Supplementary Table 2 Spearman's Correlations for continuous clinical and demographic variables and mGluR5 (mRNA, total and dimer), Norbin, Tamalin and Preso1 
protein levels in the postmortem dorsolateral prefrontal cortex. Significant values (p<0.05) are highlighted in bold.
Variable 





































Brain pH r = 0.267 r = 0.001 r = 0.006 r = 0.123 r = -0.021 r = -0.062 r = 0.137 r = 0.002 r = -0.133 r = -0.028 r = -0.150 r = 0.110 r = 0.351 r = 0.063 r = 0.176 r = 0.175 r = 0.096 r = -0.078 
  p = 0.021 p = 0.994 p = 0.960 p = 0.297 p = 0.860 p = 0.598 p = 0.420 p = 0.992 p = 0.431 p = 0.870 p = 0.375 p = 0.517 p = 0.033 p = 0.714 p = 0.303 p = 0.301 p = 0.574 p = 0.645 
Age at Death r = -0.242 r = -0.037 r = 0.012 r = -0.009 r = 0.175 r = 0.108 r = -0.417 r = -0.110 r = 0.103 r = 0.171 r = 0.353 r = 0.218 r = -0.106 r = 0.192 r = 0.095 r = -0.193 r = 0.012 r = 0.009 
  p = 0.037 p = 0.758 p = 0.920 p = 0.939 p = 0.136 p = 0.358 p = 0.010 p = 0.524 p = 0.543 p = 0.311 p = 0.032 p = 0.194 p = 0.531 p = 0.261 p = 0.580 p = 0.253 p = 0.946 p = 0.959 
RNA integrity number r = 0.229 r = 0.038 r = 0.134 r = 0.122 r = 0.069 r = 0.098 r = 0.050 r = -0.061 r = 0.047 r = 0.046 r = -0.102 r = -0.020 r = 0.437 r = 0.176 r = 0.355 r = 0.312 r = 0.305 r = 0.265 
p = 0.050 p = 0.748 p = 0.258 p = 0.301 p = 0.560 p = 0.408 p = 0.767 p = 0.724 p = 0.784 p = 0.788 p = 0.547 p = 0.905 p = 0.007 p = 0.306 p = 0.034 p = 0.060  p = 0.066 p = 0.113 
Post-mortem interval r = 0.124 r = -0.055 r = 0.174 r = 0.132 r = 0.102 r = 0.002 r = -0.017 r = -0.179 r = -0.081 r = 0.155 r = 0.184 r = 0.119 r = 0.213 r = -0.066 r = 0.273 r = -0.259 r = 0.083 r = -0.027 
  p = 0.292 p = 0.649 p = 0.140 p = 0.262 p = 0.385 p = 0.987 p = 0.921 p =0.297 p = 0.636 p = 0.358 p = 0.275 p = 0.483 p = 0.205 p =0.703 p = 0.107 p = 0.122 p = 0.623 p = 0.874 
Freezer storage time r = 0.043 r =0.221 r = 0.146 r = -0.132 r = -0.446 r = -0.369 r = 0.301 r = 0.501 r = 0.275 r = -0.348 r = -0.533 r = -0.391 r = -0.254 r = -0.373 r = -0.446 r = -0.375 r = -0.242 r = -0.245 
  p = 0.715 p = 0.062 p = 0.217 p = 0.001 p < 0.001 p = 0.001 p = 0.070 p =0.002 p = 0.099 p = 0.035 p< 0.001 p = 0.017 p = 0.129 p =0.025 p = 0.006 p = 0.022 p = 0.149 p = 0.145 
Brain weight r = 0.270 r = -0.009 r = -0.114 r = 0.120 r = 0.065 r = 0.039 r = 0.181 r = -0.022 r = -0.189 r = 0.055 r = -0.001 r = 0.110 r = 0.398 r = 0.057 r = -0.061 r = -0.023 r = 0.084 r = -0.103 
  p = 0.020 p = 0.940 p = 0.339 p = 0.309 p = 0.581 p = 0.740 p = 0.282 p =0.899 p = 0.263 p = 0.747 p = 0.993 p = 0.515 p = 0.015 p =0.470 p = 0.724 p = 0.895 p = 0.620 p = 0.543 
Age of disease onset - - - - - - - - - - - - r = -0.213 r = 0.130 r = -0.072 r = -0.362 r = -0.108 r = -0.364 
  - - - - - - - - - - - - p = 0.206 p =0.450 p = 0.674 p = 0.028 p = 0.524 p = 0.027 
Duration of illness - - - - - - - - - - - - r = -0.009 r = 0.120 r = 0.082 r = -0.076 r = -0.079 r = 0.172 
  - - - - - - - - - - - - p = 0.959 p =0.486 p = 0.634 p = 0.654 p = 0.641 p = 0.308 
Lifetime antipsychotic 
drug medication 
- - - - - - - - - - - - r = 0.038 r = 0.015 p = 0.051 r = 0.043 r = 0.037 r = -0.030 
- - - - - - - - - - - - p = 0.823 p =0.932 p = 0.768 p = 0.802 p = 0.826 p = 0.861 
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Supplementary Table 3 Spearman's correlations for associations between mGluR5 (total and dimer 
protein measures, and mRNA) and novel mGluR5 signaling partners, Norbin, Tamalin and Preso1 
protein levels in the dorsolateral prefrontal cortex of the postmortem schizophrenia brain. Significant 
values (p<0.05) are highlighted in bold.     
CONTROL 
mGluR5 total mGluR5 dimer mGluR5 expression 
(protein) (protein) (mRNA) 
mGluR5(tot)  -  r = 0.512 r = 0.361 
(protein)  -  p = 0.001 p = 0.030 
mGluR5(dim) r = 0.512  -  r = 0.050 
(protein) p = 0.001  -  p = 0.770 
mGluR5 r = 0.361 r = 0.050  -  
(mRNA) p = 0.030 p = 0.770  -  
Norbin r = -0.657 r = -0.227 r = -0.500 
(protein) p < 0.001 p = 0.018 p = 0.002 
Tamalin r = -0.560 r = -0.196 r = -0.470 
(protein) p < 0.001 p = 0.254 p = 0.003 
Preso1 r = -0.428 r = -0.367 r = -0.372 
(protein) p = 0.009 p = 0.026 p = 0.023 
SCHIZOPHRENIA 
mGluR5 total mGluR5 dimer mGluR5 expression 
(protein) (protein) (mRNA) 
mGluR5(tot)  -  r = 0.608 r = 0.059 
(protein)  -  p < 0.001 p = 0.732 
mGluR5(dim) r = 0.608  -  r = 0.125 
(protein) p < 0.001  -  p = 0.468 
mGluR5 r = 0.059 r = 0.125  -  
(mRNA) p = 0.732 p = 0.468  -  
Norbin r = 0.096 r = 0.388 r = 0.466 
(protein) p = 0.578 p = 0.019 p = 0.004 
Tamalin r = 0.202 r = 0.175 r = 0.051 
(protein) p = 0.238 p = 0.307 p = 0.764 
Preso1 r = 0.080 r = -0.069 r = -0.009 
(protein) p = 0.644 p = 0.689 p = 0.960 
 
 
 
